Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Masitinib is being investigated in the treatment of amyotrophic lateral sclerosis (ALS)
Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.
Receptos to initiate Phase 3 trial of RPC1063 in relapsing multiple sclerosis
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
ARESTIN®
Teriflunomide for multiple sclerosis.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration.
Reliable volumetry of the cervical spinal cord in MS patient follow-up data with cord image analyzer (Cordial).
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
A gender gap in autoimmunity.
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis
GEMS Project: A Platform to Investigate Multiple Sclerosis Risk.

Pages